Emtricitabine Completed Phase 4 Trials for Human Immunodeficiency Virus (HIV) Infections Prevention

IndicationsStatusPurposePhase
CompletedPrevention4
clinicaltrials.gov IdentifierTitleDrugs
NCT01576731Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)
NCT01533272Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP)
NCT02732730Uptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study
NCT02401230PrEP, Lube, and the Rectal Mucosa in MSM at Risk of HIV
NCT02206555PrEP Demonstration Project (PRELUDE Study)
NCT02198443Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open.
NCT02149888PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5
NCT02065986Pre-exposure Option for Reducing HIV in the UK.(PROUD)
NCT01214759Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
NCT00594646HIV Non Occupational Post-Exposure Prophylaxis (PEP)
NCT01855867HIV Non-Occupational Post-Exposure Prophylaxis
NCT02211690The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis